RNA interference (RNAi), a mediator of gene silencing, has swiftly become one of the most exciting and applicable biological discoveries. There has been rapid progress in identifying RNAi pathway components and elucidating the mechanisms of microRNA (miRNA) biogenesis and gene suppression. As a result, RNAi technologies have been successfully employed in a variety of systems as biological tools, and studies are underway to test the therapeutic utility of RNAi. In the span of several years, significant advances in the delivery of inhibitory RNAs in the nervous system have been made. We have glimpses into how endogenous miRNAs interface with neuronal development and function; in addition, RNAi has shown therapeutic efficacy in several mouse models of human neurological conditions. In this review, we summarize the current state-of-the-art of RNAi and its utility to neuroscientists.
RNA interference (RNAi) refers to the mechanism of gene silencing imparted by small noncoding RNAs with varying levels of sequence complementarity to an mRNA target. RNAi has evolved from a confusing experimental result in plant and worm studies to a now well-characterized process of gene expression control in multiple species. The recent awarding of the Nobel Prize in Medicine & Physiology to researchers C. Mello and A. Fire for the discovery of RNAi (Fire et al., 1998) solidifies its standing among one of the major discoveries in cell biology.
RNAi for regulation of gene expression occurs naturally in cells via microRNAs (miRNAs) and likely other noncoding RNAs. miRNAs are transcribed by RNA polymerase II as primary miRNAs (Cai et al., 2004; Lee et al., 2004) or, for a subset of miRNAs, polymerase III (Borchert et al., 2006) (Figure 1 ). In mammalian systems and worms, pri-miRNAs are processed by Drosha-DGCR8, the microprocessor complex, to an 60-70 nucleotide pre-miRNA (Gregory et al., 2004; Lee et al., 2003; Yeom et al., 2006; Zeng et al., 2005) . In flies, the microprocessor components are termed Drosha and Pasha (Denli et al., 2004) . Pre-miRNAs are subsequently exported to the cytoplasm (Lund et al., 2004; Yi et al., 2003) and processed further by Dicer-1-TRBP in mammals Provost et al., 2002) , Dicer-1-Loquacious in Drosophila (Forstemann et al., 2005; Saito et al., 2005) , or Dicer-RDE-4 in C. elegans (Grishok et al., 2001; Tabara et al., 2002) , yielding 21 bp small duplex RNAs. In mammalian cells, TRBP recruits Ago2 , a component of the miRNA-induced silencing complex (miRISC), after which final miRNA maturation and gene silencing occurs (Chu and Rana, 2006; Gregory et al., 2005) .
miRNAs in Neuroscience
Investigators in neuroscience are now capitalizing on the discovery of RNAi in a variety of ways. Primary among them is profiling miRNAs in development and disease to better understand their expression patterns, identifying miRNA targets to reveal their biological role, and as a tool to inhibit gene expression in cells and animals. miRNA profiling is being assessed by various approaches. Direct cloning and miRNA microarrays have been used to identify tissue-specific miRNAs but typically do not resolve to the cellular level. In situ hybridization and the use of RNAi sensors (reporters containing artificial miRNA binding sites in the 3 0 UTR) are more suitable strategies for identifying cell-type-specific miRNAs (Bentwich et al., 2005; Johnston and Hobert, 2003; Kloosterman et al., 2006; Liang et al., 2005; Mansfield et al., 2004; Mourelatos et al., 2002; Nelson et al., 2004 Nelson et al., , 2006 . With the latter approach, silencing of the reporter occurs in cells that express the corresponding miRNAs (Brennecke et al., 2003; Johnston and Hobert, 2003) . The RNAi sensor method has been applied to neuronally expressed miRNAs in invertebrates (Johnston and Hobert, 2003) , and proof-of-principle studies in mouse peripheral tissues have been reported (Mansfield et al., 2004) . miRNA expression is often temporally and spatially restricted at the cellular and subcellular level, imparting roles in brain morphogenesis (Aboobaker et al., 2005; Giraldez et al., 2005; Mansfield et al., 2004; Nelson et al., 2006; Vo et al., 2005) and neuronal cell fate (Krichevsky et al., 2003; Conaco et al., 2006; Krichevsky et al., 2006; Smirnova et al., 2005; Wu and Xie, 2006) . For example, Conaco and colleagues recently showed that some miRNAs are repressed by the RE1 induced silencing factor (REST) in nonneuronal cells. When REST-mediated repression of the miRNAs was relieved, a neuronal phenotype was promoted in part through miRNA-mediated inhibition of nonneuronal protein expression (Conaco et al., 2006) . In worms, asymmetric expression of miRNAs lys-6 and miR-273 in sensory neurons establishes chemosensory laterality (Chang et al., 2004b; Johnston and Hobert, 2003) . Recent evidence suggests that asymmetric miRNA expression may also occur in vertebrates. Wheeler and colleagues cloned CNS-specific miRNAs and showed by in situ hybridization that miR-500 was expressed strongly in the right versus the left developing limb bud (Wheeler et al., 2006) . At the cellular level, polarity of miRNA expression is exemplified by miR-134a (Schratt et al., 2006) . miR134a is localized to the synapse of hippocampal neurons and contributes to dendritic spine development by inhibiting expression of Limk1, a dendritically translated protein.
Target identification is of paramount importance to understanding the biological function of miRNAs. Bioinformatic approaches have been developed by a number of investigators (Krek et al., 2005; Kruger and Rehmsmeier, 2006; Lewis et al., 2003; Xie et al., 2005) , but as yet, the number of putative targets for miRNA-mediated silencing far outnumber those that have been experimentally confirmed. The predictive power of many programs is crippled in part because only a small region of the miRNA, known as the seed region (Lewis et al., 2005) , needs to retain base-pairing with the mRNA target to mediate translational repression (Didiano and Hobert, 2006; Sethupathy et al., 2006) . Wet-lab techniques for the identification of miRNA targets have also been developed. One method uses differential centrifugation to identify mRNAs that shift to the heavy polyribosome fractions following inhibition of a particular miRNA (Nakamoto et al., 2005) . Recently, Vinther and colleagues cleverly employed a stable isotope labeling approach to the problem. Identification of miRNA targets was accomplished by comparing LC-MS/MS data of tryptic peptides acquired from cells grown in media containing stable heavy isotope-labeled amino acids plus the query miRNA to mock-transfected cells grown in naturally occurring amino acids (Vinther et al., 2006) .
RNAi as a Tool
The utility of RNAi as a biological tool is limited primarily by our ability to introduce inhibitory sequences into desired cells or tissues. Inhibitory RNAs can be designed to mimic primary miRNA stem-loops, processed pre-miRNAs (short-hairpin RNAs or shRNAs), or mature miRNAs with perfect complementarity to their targets (small interfering RNAs or siRNAs) (Figure 1 ). siRNAs and shRNAs were among the first to be used in cell-free, cell culture, and animal systems. siRNAs are double-stranded effecter molecules, generally 19-22 bp in length, that are loaded directly into RISC following transfection into cells (Elbashir et al., 2001) . shRNAs are stem-loop structures expressed from vector systems, generally with strong, constitutive Pol III promoters (Paul et al., 2002; Sui et al., 2002) , although Pol II systems can be used (Xia et al., 2002) . Since shRNAs are expressed in the nucleus, they are designed to mimic Drosha-processed pre-miRNAs for efficient nuclear export. More recently, investigators have embedded siRNA sequences into pri-miRNA stem-loop structures that enter the RNAi pathway upstream of Drosha (Zeng et al., 2002) . This approach more naturally resembles endogenous RNAi, thus improving subsequent processing steps (Boden et al., 2004) . Polycistronic transcripts containing multiple stem-loops have been developed for targeting different sequences within a particular mRNA or targeting multiple unique mRNAs (Chung et al., 2006) . Engineered miRNAs serving as siRNA shuttles have also been inserted into introns or the 3 0 UTR of reporters (Cai et al., 2004; Lin and Ying, 2006) .
Designing Inhibitory RNAs
Effective RNAi requires careful consideration of the sequences used for silencing target mRNAs. siRNAs may be ineffective if the inappropriate (sense) strand is preferentially loaded over the intended guide (antisense) strand. However, this problem can usually be avoided by designing siRNA duplexes with lower thermodynamic stability at the 5 0 end of the antisense strand (Khvorova et al., 2003; Schwarz et al., 2003) . This not only promotes loading of the appropriate guide strand, but reduces the likelihood of off-targeting mediated by the sense strand (discussed below). Even with appropriate strand loading, an siRNA may still be nonfunctional if the sequence within the targeted transcript is inaccessible due to secondary and tertiary structures or associated proteins (Brown et al., 2005; Overhoff et al., 2005) . Thus, several candidate siRNAs must be screened initially to identify effective gene silencers. Various web-based programs may assist candidate selection by identifying target sites that satisfy strand-biasing guidelines and additional criteria that promote effective silencing and reduce off-targeting (Naito et al., 2004) .
Candidate siRNAs may be screened by various means to identify sequences that mediate the level of silencing that best suits the researchers' needs. Cell-free assays have been successfully employed to measure siRNAmediated cleavage of radio-labeled target mRNAs (Elbashir et al., 2001 ). This direct approach allows confirmation that the mRNA is cleaved within the target site. Alternatively, gene silencing can be assessed by real-time quantitative PCR (preferred) or Western blot analysis (dependent upon protein half-life) following transfection of RNAi into cell cultures. With this method, the target mRNA may be expressed endogenously or from cotransfected plasmids (Paul et al., 2002; Sui et al., 2002; Xia et al., 2002 Xia et al., , 2004 . The latter approach is generally done in cells that are highly transfectable (e.g., HEK293). The approach is efficient since most cells receive both target and inhibitory RNA (or plasmid expressing such) due to the nature of transfection, and both are expressed at roughly the same time. This provides a good method for screening inhibitory RNAs and certainly makes sense for targets expressed only in neurons. Conversely, silencing of endogenous mRNAs may be limited by transfection efficiency, particularly when the treated population is analyzed as a whole. For large-scale screens, the use of reverse transfection (overlaying cells onto siRNA-spotted slides, Mousses et al., 2003) coupled with luciferase or fluorescent-tagged targets may expedite candidate siRNA identification.
The Side Effects of Silencing
The specificity of RNAi must be considered for its application as a biological or therapeutic tool. While many studies support the potency and specificity of siRNA approaches, the issue of specificity across tissues and cell types remains unresolved, as microarray studies have revealed both specificity and the lack of it (Chi et al., 2003; Jackson et al., 2003; Semizarov et al., 2003) .
Off-targeting may occur if siRNAs bind to and regulate unintended mRNA targets. There are algorithms available that predict potential transcripts that may be unintentionally silenced due to partial complementarity (Naito et al., 2004; Yamada and Morishita, 2005) . Off-targeting is primarily mediated through the seed region, which may direct translational repression of unintended targets, through pairing with the 3 0 untranslated region of an mRNA (Birmingham et al., 2006) . Testing several functional sequences against a target and, if possible, performing rescue studies will help address whether off-target effects are confounding experimental results. Furthermore, for siRNAs, addition of 2 0 -O-methyl modifications to the seed regions greatly limits off-target gene silencing (Fedorov et al., 2006; Jackson et al., 2006) .
More than 20 years ago it was shown that long dsRNAs, when introduced into mammalian cells, would activate innate immune responses mediated by PKR and interferon (IFN), resulting in global gene silencing (Manche et al., 1992; Minks et al., 1979) . It is now clear that some siRNAs and shRNAs can induce IFN responses in a dose-and sequence-dependent manner in vitro (Bridge et al., 2003; Fish and Kruithof, 2004; Pebernard and Iggo, 2004; Sledz et al., 2003) . In slice culture neurons, some shRNAs activated IFN via PKR resulting in phenotypic changes (i.e., altered electrophysiological readouts and loss of synapses and dendritic spines) (Alvarez et al., 2006) . These findings reiterate the importance of validating RNAi experiments by testing several sequences. In addition to responses mediated by PKR, siRNAs may also activate IFN via tolllike receptors (TLR) TLR7 and TLR8, which recognize siRNAs within the endosome (Hornung et al., 2005; Marques and Williams, 2005) . Recently, immunostimulatory sequence motifs have been identified that should be avoided when selecting RNAi target sequences (Hornung et al., 2005; Judge et al., 2005) . Furthermore, modifying the siRNAs at the termini of the sense strand significantly reduces the immunostimulatory activity (Hornung et al., 2005; Morrissey et al., 2005) .
Engineered siRNAs, shRNAs, and miRNAs utilize endogenous RNAi machinery and can therefore at high doses cause toxicity independent of sequence. shRNAs are designed to resemble pre-miRNAs and are typically expressed at high levels. Abundant shRNAs likely outcompete endogenous pre-miRNAs for nuclear export machinery, which may result in cellular toxicity (Grimm et al., 2006) . Changing the inhibitory RNA from a shRNA to one that is pri-miRNA-based can greatly reduce nuclear accumulation and subsequent toxicity due to saturation of endogenous machinery (R.L.B. and B.L.D., unpublished data). This effect is mostly attributable to dosing; engineered pri-miRNAs may be less well transcribed or less stable than optimized shRNAs. To date there is no evidence that siRNAs are capable of saturating RNAi machinery but, as stated above, can be problematic at doses greater than 10 nM. Thus, sequences that reduce expression of the intended target at high picomolar to low nanomolar doses (in vitro) are ideal.
RNAi for Neuroscientists: Applications
Researchers have induced RNAi experimentally through the exogenous addition of siRNAs or through the use of vectors expressing shRNAs or engineered pri-miRNAs to a variety of biological systems (Figure 2) . In C. elegans, exogenously triggered RNAi directed at target genes is often accomplished by generating transgenic lines expressing shRNA transgenes from inducible and/or tissue-specific promoters (Wang and Barr, 2005) . Interestingly, in wildtype worms, neurons are resistant to RNAi administered via feeding of bacteria expressing dsRNA (Kamath et al., 2003) . However, mutant lines with neurons sensitive to this delivery method have been generated and used for RNAi screens to identify genes important to neuronal synapse development and function (Sieburth et al., 2005) . RNAi screens in neurons have also been successful in Drosophila. Several genes, including transcription factors required for proper development of the embryonic nervous system, were identified following injection of dsRNA libraries into fly embryos (Ivanov et al., 2004; Parrish et al., 2006) .
In general, cultured neurons are not easily transfected with plasmid DNAs using most commercial reagents. Because siRNAs need merely enter cytoplasmic RISC for silencing activity, the cell membrane poses the main transfection barrier, making them more amenable than plasmids to standard transfection protocols. Researchers often use siRNAs, either purchased commercially or generated at the bench, that can be complexed with a variety of transfection reagents, some developed specifically for siRNAs. Recent work indicates that ''dicer-ready'' siRNAs of 26-27 nucleotides are more potent than the shorter sequences in tissue culture cells (Kim et al., 2005) .
In addition to whole cells, transfection into spatially restricted areas of neurons has also been accomplished. Hengst and coworkers transfected siRNAs targeting RhoA directly into the distal axons of dorsal root ganglia (Hengst et al., 2006) . Silencing was seen in the transfected axon, but not more proximal axons or cell bodies. This approach may allow spatial resolution of mRNA transcripts in neurons at the subcellular level.
Transfection into organotypic slice cultures has also been done (Boda et al., 2004; Shima et al., 2004; Gaudilliè re et al., 2004) . To assess the role of flamingo, a member of the cadherin superfamily, in the growth and maintenance of dendrites, plasmids expressing inhibitory RNAs were conjugated with gold particles and biolistically transfected into neurons (Shima et al., 2004) . In other studies, Boda and coworkers biolistically transfected siRNAs into slice cultures to test the role of the mental retardation protein Pak3 in hippocampal synaptic plasticity, (Boda et al., 2004) .
The longevity of RNAi induced by transfection of siRNAs or dicer substrates may be insufficient for some in vitro studies (often fewer than 14 days). In these instances, viral-mediated expression of either shRNAs (GonzalezAlegre et al., 2005) or engineered pri-miRNAs (Stegmeier et al., 2005) can be used. Lentivirus-based vector systems are often employed for cell culture work because they are simple and inexpensive to make. Moreover, because they integrate into the genome, they can be used to generate stable cell lines. Lentiviruses based on feline immunodeficiency virus (FIV) or human immunodeficiency virus (HIV) have been optimized to elicit stable and regulated RNAi (Harper et al., 2006; Wiznerowicz and Trono, 2003) .
Naked and complexed siRNAs have been successfully delivered to the CNS and PNS of rodents (Dorn et al., 2004; Salahpour et al., 2006; Tan et al., 2005; Thakker et al., 2004) . siRNAs can be introduced acutely or through the use of implanted pumps. Complexing siRNAs with lipids or other transfection reagents allows for lower dosing, but toxicity of the complexing agent is always a consideration. Researchers have directly injected or used pumps to deliver siRNAs to reduce expression of P2X3 in nociceptive sensory neurons, NR2B and delta opioid receptors in sensory neurons, and dopamine transporter in the striatum and substantia nigra. In addition, intraventricular injection of siRNA into neonatal mice decreased target gene expression . Using these approaches, siRNA-mediated gene silencing remains transient and typically requires continual or repeated delivery for long-term studies.
Long-term RNAi may be achieved with lentiviruses, adenoviruses, and adeno-associated viruses that have been engineered to deliver inhibitory RNAs to the nervous system. The first demonstrations of in vivo delivery to the brain were accomplished with adenoviruses expressing shRNAs targeting transgenic eGFP (Xia et al., 2002) or plasmids expressing shRNAs against agouti-related peptide (Makimura et al., 2002 ). These studies were followed shortly by in vivo delivery of RNAi via recombinant adenoassociated viruses (Harper et al., 2005; Hommel et al., 2003; Miller et al., 2005; Ralph et al., 2005; RodriguezLebron et al., 2005; Xia et al., 2004) and lentiviruses (Raoul et al., 2005; Singer et al., 2005 ) to brain, spinal cord, and muscle. To date, all vector-expressed RNAi used in silencing CNS and PNS targets has been in the form of shRNAs driven by either Pol II or Pol III expression systems. Though considerable efficacy was observed, much of the early work was done using shRNAs harboring sequences that were not optimized for guide-strand loading into RISC since rules for strand biasing were unknown at the time. With strand-biasing knowledge now in hand, more appropriate RNAi-expressing vectors can be developed for future application to neuroscience in mammals. Further improvements may be achieved by utilizing engineered pri-miRNAs that give researchers opportunities to coexpress RNAi and reporters via tissue-specific or regulated promoters, thus enhancing the versatility of RNAi in vivo (Zeng et al., 2002) .
Finally, neurobiologists have also used engineered inhibitory RNAs as novel therapeutic strategies for treating neurological disorders. Several groups have successfully employed RNAi to treat mouse models of various human neurological conditions, including Huntington's disease, Alzheimer's, Spinocerebellar Ataxia Type I, Amyotrophic Lateral Sclerosis, and pain, among others (Dorn et al., 2004; Harper et al., 2005; Makimura et al., 2002; Miller et al., 2005; Ralph et al., 2005; Raoul et al., 2005; Salahpour et al., 2006; Singer et al., 2005; Tan et al., 2005; Thakker et al., 2004; Xia et al., 2002 Xia et al., , 2004 .
The Next
Step: Regulated Expression The application of RNAi has already been enhanced with the development of controlled expression vectors. Regulated RNAi expression has been achieved via ecdysoneor tetracycline-inducible systems (Gupta et al., 2004; Matsukura et al., 2003) . Tet-based systems have been successfully incorporated into viral vectors allowing stable, inducible silencing in vitro and in vivo (Hosono et al., 2004; Shin et al., 2006; Wiznerowicz and Trono, 2003) . However, transgenic mice expressing tet-inducible RNAi have yet to be generated. To date, inducible RNAi transgenics have relied primarily upon Cre-LoxP systems (Chang et al., 2004a) . Inducible RNAi strategies provide a method to generate models where sufficient target gene expression is essential for organism development or viability. However, RNAi approaches will yield knockdowns as opposed to true knockouts produced with the traditional Cre-LoxP methods. Nonetheless, the ability to reduce gene expression with precise timing allows researchers to assess gene function during various developmental stages. Inducible systems can also be exploited to express natural miRNAs to elucidate their respective roles in developmental processes. Moreover, controlled expression can be combined with tissue-specific strategies to allow both temporal and spatial restriction of RNAi. These approaches continue to be fine-tuned for tight regulation and may also benefit therapeutic applications of RNAi.
Conclusion
We have learned much about the biochemistry underlying RNAi since the recent discovery of RNAi by Fire and Mello. However, we are only in the initial stages of understanding miRNA's role in neural development, synaptic function, animal behavior, and disease. The techniques for harnessing RNAi as a biological tool and therapeutic approach will continue to evolve as we discover new ways in which to co-opt the elegant RNAi pathway for use in neuroscience and medicine. Bentwich, I., Avniel, A., Karov, Y., Aharonov, R., Gilad, S., Barad, O., Barzilai, A., Einat, P., Einav, U., Meiri, E., et al. (2005) . Identification of hundreds of conserved and nonconserved human microRNAs. Nat. Genet. 37, 766-770.
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